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Background-—Pneumonia is complicated by high rate of mortality and cardiovascular events (CVEs). The potential benefit of
aspirin, which lowers platelet aggregation by inhibition of thromboxane A2 production, is still unclear. The aim of the study was to
assess the impact of aspirin on mortality in patients with pneumonia.
Methods and Results-—Consecutive patients admitted to the University-Hospital Policlinico Umberto I (Rome, Italy) with
community-onset pneumonia were recruited and prospectively followed up until discharge or death. The primary end point was the
occurrence of death up to 30 days after admission; the secondary end point was the intrahospital incidence of nonfatal myocardial
infarction and ischemic stroke. One thousand and five patients (age, 74.715.1 years) were included in the study: 390 were
receiving aspirin (100 mg/day) at the time of hospitalization, whereas 615 patients were aspirin free. During the follow-up, 16.2%
of patients died; among these, 19 (4.9%) were aspirin users and 144 (23.4%; P<0.001) were aspirin nonusers. Overall, nonfatal
CVEs occurred in 7% of patients, 8.3% in nonaspirin users, and 4.9% in aspirin users (odds ratio, 1.77; 95% confidence interval, 1.03
to 3.04; P=0.040). The Cox regression analysis showed that pneumonia severity index (PSI), severe sepsis, pleural effusion, and
PaO2/FiO2 ratio <300 negatively influenced survival, whereas aspirin therapy was associated with improved survival. Compared to
patients receiving aspirin, the propensity score adjusted analysis confirmed that patients not taking aspirin had a hazard ratio of
2.07 (1.08 to 3.98; P=0.029) for total mortality.
Conclusions-—This study shows that chronic aspirin use is associated with lower mortality rate within 30 days after hospital
admission in a large cohort of patients with pneumonia. ( J Am Heart Assoc. 2015;4:e001595 doi: 10.1161/JAHA.114.001595)
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C ommunity-onset pneumonia, including the epidemiolog-ical definitions of community-acquired pneumonia (CAP)
and healthcare-associated pneumonia (HCAP), is the most
common infection leading to hospitalization in intensive care
units and the most common cause of death associated with
infectious diseases.1,2 Among the causes of poor survival,
acute cardiovascular (CV) events (CVEs), which complicate
the clinical course of pneumonia, may play a relevant role;
thus, respiratory tract infections are associated with an
increased risk for vascular disease, such as myocardial
infarction (MI) and stroke, which usually occur in the early
phase of pneumonia.3–8
Aspirin is an anti-inflammatory drug, which significantly
lowered the rate of MI and stroke in primary and secondary
intervention trials by irreversible acetylation of cyclooxygen-
ase 1 (COX1) and ensuing impaired formation of thromboxane
A2.9,10 Previous studies found increased platelet activation in
patients affected by viral upper respiratory tract infection or
pneumonia,11,12 suggesting that lung infection could be a
trigger for platelet activation, but the impact of such changes
on survival in patients with pneumonia is still unclear. Thus,
data regarding the impact of aspirin on survival after
pneumonia are few and equivocal.13,14 Furthermore, no data
on the association between aspirin use and CVEs have been
reported thus far in patients with pneumonia. In this prospec-
tive, observational study, we investigated whether aspirin use
affects early (within 30 days) mortality and CVEs in patients
with community-onset pneumonia during follow-up.
From the Departments of Public Health and Infectious Diseases (M.F., A.R.,
A.F., P.P., M.V.), Internal Medicine and Medical Specialties (R.C., C.C., F.B.,
F.V.), Emergency Medicine (M.G.S., G.B.), and Clinical Medicine (G.T.),
Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy.
Correspondence to: Francesco Violi, MD, Department of Internal Medicine
and Medical Specialties, Policlinico Umberto I, “Sapienza” University of Rome,
Viale dell’Universita 37, 00161 Rome, Italy.
E-mail: francesco.violi@uniroma1.it
Marco Falcone, MD, Department of Public Health and Infectious Diseases,
Policlinico Umberto I, “Sapienza” University of Rome, Viale dell’Universita 37,
00161 Rome, Italy. E-mail: marco.falcone@uniroma1.it
Received November 12, 2014; accepted December 5, 2014.
ª 2015 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.114.001595 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on March 24, 2019
Patients and Methods
Study Design and Patient Selection
The study was conducted at the University-Hospital Policlinico
Umberto I (Rome, Italy). All patients admitted to medical
wards with diagnosis of community-onset pneumonia through
the emergency department (ED) from January 2011 to
December 2013 were consecutively recruited and prospec-
tively followed up. Patients who fulfilled the following criteria
were enrolled in the study after giving written informed
consent: (1) age 18 years or over; (2) clinical presentation of
an acute illness with 1 or more of the following signs or
symptoms suggesting pneumonia: presence of rales, rhonchi,
bronchial breath sounds, fever (>38.0°C), tachycardia, chills,
dyspnea, coughing (with or without sputum), or chest pain;
and (3) presence of new consolidation(s) on chest X-ray.
Pneumonia was considered as CAP if it was diagnosed upon
hospitalization and the patient had not been discharged from
an acute care facility within 14 days preceding the clinical
presentation. We classified patients as having HCAP if they
had attended a hospital or hemodialysis clinic or received
intravenous chemotherapy in the past 30 days, had been
admitted to an acute-care hospital for at least 2 days or had
surgery in the past 90 days, or resided in a nursing home or
long-term care facility.15 We classified patients as having
hospital-acquired pneumonia (HAP) if they received their
diagnosis after being hospitalized for more than 72 hours or
within 10 days of leaving the hospital.
Patients were excluded from the study if 1 of the following
criteria was applied: radiographic evidence of a preexisting
infiltrates, criteria for HAP, pregnancy or breastfeeding,
documented severe allergy to antibiotics, or refusal to sign
informed consent. All patients were followed up during
hospitalization and for 30 days after admission or until death.
The present study was conducted according to the principles
stated in the Declaration of Helsinki. The institutional review
board approved this prospective, observational study.
Baseline Assessment and Follow-up
Data on demographic characteristics, comorbidities, and
antibiotic and concomitant therapy were collected; severity
of illness at presentation was quantified by the pneumonia
severity index (PSI) and CURB-65 score.16
Type-2 diabetes mellitus, hypertension, history of coronary
heart disease, dyslipidemia, peripheral arterial disease, and
chronic obstructive pulmonary disease (COPD) were defined
as previously described.17,18 Baseline treatments were
defined according to the patients’ pharmacological history.
Severe sepsis was defined as sepsis with sepsis-induced
organ dysfunction or tissue hypoperfusion (manifesting as
hypotension, elevated lactate, or decreased urine output) and
septic shock as severe sepsis plus persistently low blood
pressure following the administration of intravenous fluids.19
Patient status was assessed by the Sequential Organ
Failure Assessment (SOFA) score.20 Antibiotic therapy was
initiated in the ED in accord with the hospital guidelines and/
or consultation of an infectious diseases specialist. Patients
were followed up for 30 days from hospital admission or until
death.
Study End Points
The primary study end point was the occurrence of death up
to 30 days after hospital admission.
Secondary end points were the in-hospital occurrence of a
nonfatal ischemic CVE (including MI and ischemic stroke).
MI criteria were those of the “Third Universal Definition of
Myocardial Infarction”: the detection of a rise of cardiac
troponin with at least 1 value above the 99th percentile upper
reference limit was associated with at least 1 of the following:
(1) chest pain; (2) detection of new or presumably new
significant ST-segment–T wave changes or new left bundle
branch block (LBBB); (3) development of pathological Q waves
in the electrocardiogram (ECG); (4) de novo imaging evidence
of viable myocardium loss or regional wall motion abnormal-
ity; (5) identification of an intracoronary thrombus by
angiography or autopsy; and (6) cardiac death with symptoms
suggestive of myocardial ischemia and presumed new ische-
mic ECG changes or new LBBB. ST elevation MI and non-ST
elevation MI were defined as previously reported.21
The occurrence of stroke was determined based on clinical
manifestations and confirmed by computed tomography scan.
Blind adjudication of the events was performed by 2
independent cardiologists (C.C. and F.B.), who did not
participate in the patients’ recruitment and follow-up.
Aspirin Treatment
The population was divided in 2 groups: patients taking aspirin
before and during hospitalization (aspirin group) and patients
not taking aspirin before and during hospitalization (nonaspi-
rin group). Compliance with aspirin and the other drugs was
daily monitored.
Statistical Analysis
The results obtained were analyzed using commercially
available statistical software packages (SPSS, version 20.0;
SPSS, Inc., Chicago, IL and R, version 3.0.2; R development
core team, Vienna, Austria).
The sample size was planned using a log-rank test for
comparing mortality rate in patients receiving or not the
DOI: 10.1161/JAHA.114.001595 Journal of the American Heart Association 2
Aspirin Reduces Mortality in Pneumonia Falcone et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 24, 2019
aspirin. With a minimum follow-up time of 30 days, assuming
a 1.5 to 1 ratio for number of controls versus treated, an
incidence rate of mortality in the control group of 18%,22 and
a reduction of mortality by aspirin of at least 5.5%
(corresponding to a hazard ratio [HR] of 0.82 and a relative
reduction of approximately 30%), we planned a sample size of
975 patients. This guarantees a power of at least 80% at a
fixed a type I error rate of 5%.
To detect significant differences between groups, we used
the chi-square test or Fisher exact test for categorical
variables and the 2-tailed t test or Mann-Whitney test for
continuous variables, when appropriate. Survival curves for
time-to-event variables were constructed with the use of
Kaplan–Meier estimates based on all available data and were
compared with the use of the log-rank test. In a multivariate
analysis of survival, the Cox regression model was used to
determine the effects of different variables on overall survival.
The bivariate effect of aspirin treatment on the secondary end
point (in hospital nonfatal CVEs) was assessed by means of a
logistic regression model. Wald confidence intervals (CIs) and
tests for odds ratios (ORs) were computed based on the
estimated standard errors. The proportionality of hazards
assumption for the Cox model has been checked using plots
of Schoenfeld residuals.
Finally, in order to correct for possible bias arising from the
observational nature of the experiment, we corrected all
relevant effect estimates and P values with the propensity
score estimated using all prehospitalization variables (age,
gender, previous therapies, comorbidities, signs, and symp-
toms at hospitalization). In detail, we built the propensity
scores by considering all variables for possible prediction of
the treatment indicator and performing forward step-wise
selection for parsimony. After, the estimated propensity score
has been used as a predictor in multivariate models assessing
the relationship between treatment and outcomes. The
balancing properties of the propensity score have been
assessed by evaluating the propensity score adjusted sum-
maries within each treatment group. Propensity score
adjusted estimates can be expected to be close to the
estimates that would be obtained had the treatment been
randomized.23 Statistical significance was established at
≤0.05. All reported P values are 2-tailed.
Results
During the study period, a total of 1452 patients were
assessed for eligibility, and 1005 were finally included in the
study. A consort diagram describing the study flow is
presented in Figure 1.
Among the patients included in the study, 390 were
analyzed as the “aspirin group” (100 mg/day) and 615 as the
“nonaspirin group.” Comparison of demographics and clinical
features of patients included in the aspirin and nonaspirin
groups are summarized in Table 1. Comparison between
aspirin and nonaspirin groups after propensity score adjust-
ment, showing the balance between the 2 study groups with
respect to baseline characteristics, is reported in Table 2.
No differences in demographic characteristics were
recorded between the 2 study groups, but patients included
Figure 1. Study flow diagram. ED indicates emergency department; HAP, hospital-acquired pneumonia.
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in the aspirin group showed a higher frequency of chronic
heart failure and belonged to the lower-severity classes of PSI
and CURB-65 scores. Compared to the nonaspirin group,
patients on aspirin showed a lower incidence of pleural
effusion and a minor degree of respiratory impairment; they
also had a lower median SOFA score (1.8 vs. 2.5; P=0.02).
Moreover, patients on aspirin had a lower incidence of severe
sepsis or septic shock (4.6% vs. 11.5%; P<0.001).
During the follow-up, 163 patients (16.2%) died; demo-
graphics and clinical features of survivors and nonsurvivors
are reported in Table 3. Patients who died were older, had a
higher incidence of comorbidities, and a greater severity of
pneumonia according to PSI and CURB-65 scoring systems.
Furthermore, nonsurvivors had a higher median SOFA score
(3.9 vs. 2.1; P<0.001) and higher incidence of severe sepsis
or septic shock (23.9% vs. 5.9%; P<0.001). Finally, patients
who died were less frequently on aspirin therapy (11.7% vs.
44.1%; P<0.001).
Compared to the nonaspirin group, patients on aspirin
showed a lower incidence of in-hospital 30-day mortality
(23.4% vs. 4.9%; P<0.001). Intrahospital nonfatal CVEs
occurred in 70 patients (7.0%); 8.3% of patients in the
nonaspirin group and in 4.9% of patients in the aspirin group,
showing an increased risk for patients not taking aspirin (OR,
1.77; 95% CI, 1.03 to 3.04; P=0.040).
As shown in Figure 2, Kaplan–Meier analysis on estimated
survival during hospitalization showed improved survival of
the aspirin group, compared to the nonaspirin group
(P<0.001). Table 4 describes Cox regression analysis about
effects of different variables on overall survival during follow-
up. Whereas a PSI V class, severe sepsis or septic shock,
pleural effusion, and PaO2/FiO2 ratio <300 negatively
Table 1. Clinical Characteristics of Aspirin- Versus Non-Aspirin-Treated Patients
Variables
Aspirin Group
n=390 Patients
Nonaspirin Group
n=615 Patients P Value
Age, y 73.617.4 75.312.8 0.08
Male sex 215 (55.1%) 375 (61.0%) 0.067
PSI II to III classes 130 (33.3%) 58 (9.4%) <0.001
PSI IV class 206 (52.8%) 299 (48.6%) 0.194
PSI V class 54 (13.8%) 258 (42.0%) <0.001
CURB-65 I class 195 (50%) 219 (35.6%) <0.001
CURB-65 II class 153 (39.2%) 211 (34.3%) 0.1
CURB-65 III class 42 (10.7%) 185 (30.1%) <0.001
Chronic heart disease 175 (44.9%) 134 (21.7%) <0.01
Chronic hepatitis 31 (7.9%) 61 (9.9%) 0.8
Diabetes 41 (10.5%) 151 (24.5%) <0.001
Renal failure 62 (16%) 131 (21.3%) 0.1
COPD 128 (32.8%) 198 (32.2%) 0.8
CAP 271 (69.4%) 356 (57.8%) 0.02
HCAP 119 (30.5%) 259 (42.2%) 0.03
Neoplasm 50 (12.9%) 179 (29.1%) <0.001
Pleural effusion 86 (22.1%) 338 (54.9%) <0.001
Immunosuppressive therapy 52 (13.3%) 84 (13.6%) 0.5
Fever >38°C 224 (57.4%) 330 (53.6%) 0.5
PaO2/FiO2 ratio <300 26 (6.6%) 156 (25.3%) <0.001
NIV 2 (0.5%) 29 (4.7%) <0.001
SOFA score >2 142 (36.4%) 503 (81.8%) <0.001
Severe sepsis or septic shock 18 (4.6%) 71 (11.5%) <0.001
Nonfatal cardiovascular events 19 (4.9%) 51 (8.3%) 0.03
CAP indicates community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; HCAP, healthcare-associated pneumonia; NIV, noninvasive ventilation;
PSI, pneumonia severity index; SOFA, Sequential Organ Failure Assessment.
DOI: 10.1161/JAHA.114.001595 Journal of the American Heart Association 4
Aspirin Reduces Mortality in Pneumonia Falcone et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 24, 2019
influenced survival, aspirin therapy was associated with lower
mortality rate. This finding was confirmed by the propensity
score adjusted estimates, given that patients of the nonas-
pirin group had an HR of 2.07 (95% CI, 1.08 to 3.98; P=0.029),
compared to patients receiving aspirin.
Discussion
The relevant finding of our prospective, observational study is
that patients with community-onset pneumonia on chronic
treatment with aspirin have a lower 30-day mortality rate,
compared to those not receiving aspirin.
The overall mortality rate observed in our population
(16.2%) is comparable to that previously reported by Ruhnke
et al.,24 who observed, in hospitalized patients with CAP in
the United States, a short-term morality rate ranging from
11.7% in 65- to 69-year-old patients to 25.2% in patients >85;
this finding was confirmed in a recent world-wide perspective
study in which the 30-day mortality of CAP was approximately
18%.21
In the present study, we aimed at investigating whether
aspirin treatment affects mortality in patients with commu-
nity-onset pneumonia. Thus far, very few clinical studies
analyzed the clinical impact of antiplatelet drugs on clinical
outcomes in patients with pneumonia. A retrospective study
in elderly patients hospitalized for CAP showed a significant
association between the use of antiplatelet drugs (low-dose
aspirin or thienopyridines) and reduced need for intensive
care and hospital stay.13 In our population, approximately 40%
of patients were treated with aspirin during the intrahospital
stay. Whereas age and sex were equally distributed between
aspirin and nonaspirin users, patients on aspirin had a
significantly more-prevalent history of CVD, less prevalence of
Table 2. Clinical Characteristics of Aspirin- Versus Non-Aspirin-Treated Patients After Propensity Score Adjustment
Variables
Aspirin Group
n=390 Patients
Nonaspirin Group
n=615 Patients SD
Age, y 71.9916.11 73.5116.52 0.092
Male sex 53.9% 63.5% 0.097
PSI II to III classes 22.8% 17.0% 0.072
PSI IV class 58.6% 62.0% 0.035
PSI V class 18.6% 21.0% 0.030
CURB-65 I class 30.5% 32.8% 0.025
CURB-65 II class 32.4% 40.2% 0.081
CURB-65 III class 16.7% 19.7% 0.039
Chronic heart disease 21.3% 28.9% 0.088
Chronic hepatitis 8.6% 8.0% 0.030
Diabetes 12.6% 15.2% 0.038
Renal failure 11.6% 13.8% 0.033
COPD 29.4% 30.2% 0.009
CAP 18.4% 21.9% 0.044
HCAP 81.6% 78.1% 0.044
Neoplasm 13.7% 17.0% 0.046
Pleural effusion 25.5% 33.2% 0.085
Immunosuppressive therapy 11.0% 14.6% 0.054
Fever >38°C 57.4% 51.8% 0.056
PaO2/FiO2 ratio <300 4.5% 5.0% 0.012
NIV 0.6% 3.5% 0.103
SOFA score >2 57.1% 55.6% 0.015
Severe sepsis or septic shock 5.6% 5.4% 0.004
Nonfatal cardiovascular events 6.2% 3.3% 0.068
SD <10% indicates balance. CAP indicates community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; HCAP, healthcare-associated pneumonia;
NIV, noninvasive ventilation; PSI, pneumonia severity index; SOFA, Sequential Organ Failure Assessment.
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diabetes, and lower pneumonia severity, as assessed by PSI
and CURB-65 scores; conversely, nonaspirin users had more-
prevalent neoplasm, which, however, was not significantly
associated with intrahospital mortality at Cox regression
analysis.
The novelty of the present study is that patients with
pneumonia receiving aspirin had significantly lower total
30-day mortality rate (4.9%), compared to nonaspirin users
(23.4%), and aspirin therapy was a factor independently
associated with improved survival. This finding is apparently in
contrast with a previous prospective observational study of
1007 patients admitted to the hospital with CAP, of whom
approximately 30% were on aspirin treatment; Chalmers
et al.13 found an approximate 35% risk reduction of mortality,
which, however, did not reach significance. Given that the
population included by Chalmers et al.,13 compared to our
population, was younger and had less-severe pneumonia, as
suggested by the 2-fold lower incidence of mortality, we
cannot exclude that the benefit of aspirin is observed more
prevalently in elderly patients with severe pneumonia and high
mortality rate.
Several mechanisms may account for lower mortality rate
in our pneumonia population. A previous study by Corrales-
Medina et al.25 demonstrated that the early phase of
pneumonia might be complicated by MI, which may worsen
the illness prognosis. Accordingly, we found a high rate of CV
complications, such as MI and stroke, which were signif-
icantly reduced in aspirin users, compared to nonusers. This
is consistent with our recent study showing a significant
association between platelet activation and thromboxane A2
production and MI, suggesting a role for COX1 activation as a
trigger for MI in patients with pneumonia.12 However, the
interplay among platelet activation, aspirin use, and CV
outcomes needs to be further elucidated owing to the fact
that low-dose aspirin is able to only partly inhibit platelet
activation and COX1 in patients with pneumonia.12
Table 3. Clinical Characteristics of Survived Versus Nonsurvived Patients
Variables
Survived
n=842 Patients
Nonsurvived
n=163 Patients P Value
Age (mean) 74.115.7 77.911.1 <0.001
Male sex 507 (60.2%) 83 (50.1%) 0.027
PSI II to III classes 185 (22.0%) 3 (1.8%) <0.001
PSI IV class 424 (50.4%) 81 (49.7%) 0.877
PSI V class 233 (27.7%) 79 (48.5%) <0.001
CURB-65 I class 373 (44.3%) 44 (27.0%) <0.001
CURB-65 II class 290 (34.4%) 66 (40.5%) 0.139
CURB-65 III class 179 (21.3%) 53 (32.5%) 0.002
Chronic heart disease 235 (27.9%) 54 (33.1%) 0.178
Chronic hepatitis 63 (7.5%) 32 (19.6%) <0.001
Diabetes 164 19.5%) 31 (19.0%) 0.892
Renal failure 142 (16.9%) 52 (31.9%) <0.001
COPD 284 (33.7%) 39 (23.9%) 0.014
CAP 576 (70.2%) 51 (27.5%) <0.001
Neoplasm 186 (22.1%) 47 (28.8%) 0.062
Pleural effusion 340 (40.6%) 94 (57.7%) <0.001
Immunosuppressive therapy 106 (12.9%) 30 (16.2%) 0.27
Aspin use 371 (44.1%) 19 (11.7%) <0.001
Fever >38°C 457 (54.3%) 91 (55.8%) 0.716
PaO2/FiO2 ratio <300 279 (33.1%) 103 (63.2%) <0.001
NIV 14 (1.7%) 17 (9.2%) <0.001
SOFA score (median) 2.1 3.9 <0.001
Severe sepsis or septic shock 50 (5.9%) 39 (23.9%) <0.001
CAP indicates community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; HCAP, healthcare-associated pneumonia; NIV, noninvasive ventilation;
PSI, pneumonia severity index; SOFA, Sequential Organ Failure Assessment.
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An alternative mechanism, unrelated to the reduced cardiac
complications, could also be implicated in lower mortality rate
by aspirin. Thus, experimental and clinical studies demon-
strated that platelet activation is associated with severity of
sepsis and contributes to organ failure.26–29 There is also
evidence from observational studies that aspirin treatment is
associated with less-severe sepsis and lower mortality, which
is consistent with animal studies showing that aspirin
attenuates sepsis severity.30–32 Consistently with these
reports, sepsis rate was significantly reduced in aspirin-treated
patients, suggesting that aspirin use may protect against
systemic inflammation and organ failure and eventually lower
mortality rate. In agreement with this hypothesis, patients on
aspirin treatment had significantly lower PSI and CURB-65
scores, compared to nonaspirin users.
The study has limitations and implications. The observa-
tional nature of the study is an intrinsic limitation because
the lack of randomization precludes a definite analysis of
aspirin benefit. Therefore, we believe that these findings
cannot be transferred to clinical practice until an interven-
tional study with aspirin has been done. An interventional
study with aspirin is also necessary to establish the real
impact of aspirin on total mortality, whose reduction is even
higher than that observed in patients with acute coronary
syndrome33 and needs to be confirmed in further studies. The
strength of the study is, however, the analysis of pneumonia
in the real world, which suggests that aspirin may have a
positive impact on mortality independently from other
confounding factors. In particular, aspirin and nonaspirin
users were well balanced in terms of demographic and
clinical characteristics and had no difference in concomitant
diseases, which could bias the results, with the exception of
previous CVD and neoplasm, which were more frequent in
aspirin and nonaspirin users, respectively. It is possible that
aspirin benefit may be detected in an old population, as
depicted by the present study, and therefore our data cannot
be extrapolated to a younger population affected by pneu-
monia. This should be carefully considered when planning
future randomized trials to further explore the efficacy of
aspirin in this setting.
In conclusion, we provide the first evidence that, in an old
population affected by pneumonia, aspirin treatment, though
prevalently used by patients with higher CV risk, is associated
with a lower mortality rate within 30 days from hospital
admission. Owing to the observational methodology of the
study, randomized, clinical trials are warranted to support this
finding.
Appendix
The SIXTUS study group who collaborated to the study:
Fabiana Albanese, Elisa Biliotti, Tommaso Bucci, Cinzia Myriam
Calabrese, Roberto Carnevale, Marco Casciaro, Andrea Celes-
Figure 2. Estimated survival during hospitalization of the aspirin
group, compared to the nonaspirin group, using Kaplan–Meier
survival analysis.
Table 4. Cox Regression Analysis About Effects of Different Variables on Overall Survival During Hospitalization
Variables HR 95% CI P Value
Aspirin use 0.43 0.25 to 0.75 0.003
PSI V class 1.41 1.03 to 1.93 0.035
Severe sepsis or septic shock 3.44 2.39 to 4.96 <0.001
Pleural effusion 1.53 1.10 to 213 0.011
PaO2/FiO2 ratio <300 2.27 1.58 to 3.26 <0.001
CI indicates confidence interval; HR, hazard ratio; PSI, pneumonia severity index.
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